Antiarrhythmic Agents and the Danger of Proarrhythmic Events
Authors: Mark E. Josephson
Journal: Annals of Internal Medicine (1989)

Editorials15 July 1989Antiarrhythmic Agents and the Danger of Proarrhythmic EventsMark E. Josephson, MDMark E. Josephson, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-2-101 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOnly in the last decade have the proarrhythmic effects of antiarrhythmic agents been evaluated. Most recent studies (1-3) have focused on drugs used to treat ventricular arrhythmias. These studies have dealt with patients primarily being treated for ventricular arrhythmias. The ventricular proarrhythmic effect of these agents has not been evaluated carefully when used to manage supraventricular arrhythmias despite the fact that the induction of polymorphic ventricular tachycardia by antiarrhythmic agents was initially documented in patients being treated for atrial fibrillation (4). Thus, whereas much of the attention to ventricular proarrhythmias has been on treatment of ventricular arrhythmias, similar attention must...References1. Zipes D. Proarrhythmic events. Am J Cardiol. 1988;61:70A-6A. CrossrefMedlineGoogle Scholar2. BiggerSahar JD. Clinical types of proarrhythmic response to antiarrhythmic drugs. Am J Cardiol. 1987;59:2E-9E. CrossrefMedlineGoogle Scholar3. HorowitzZipesBigger LDJ. Proarrhythmia, arrhythmogenesis, or aggravation of arrhythmia-a status report, 1987. Am J Cardiol. 1987;59:54E-6E. CrossrefMedlineGoogle Scholar4. SelzerWray AH. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation. 1964;30:17-26. CrossrefMedlineGoogle Scholar5. Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol. 1987;59:32E-7E. CrossrefMedlineGoogle Scholar6. MorganrothAndersonGentzkow JJG. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol. 1986;8:607-15. CrossrefMedlineGoogle Scholar7. BernsRinkenbergerJeangDoughertyJenkinsNaccarelli ERMAMG. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol. 1987;59:1337-41. CrossrefMedlineGoogle Scholar8. BorgeatGoyMaendlyKaufmannGrbicSigwart AJRUMU. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 1986;58:496-8. CrossrefMedlineGoogle Scholar9. KimLalRuffy SRR. Treatment of paroxysmal reentrant supraventricular tachycardia with flecainide acetate. Am J Cardiol. 1986;58:80-5. CrossrefMedlineGoogle Scholar10. Falk R. Flecainide induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med. 1989;111:107-11. LinkGoogle Scholar11. SlaterLampertPodridLown WSPB. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol. 1988;61:349-53. CrossrefMedlineGoogle Scholar12. LemeryBrugadaDellaBellaDugerniervan den DoolWellens RPPTAH. Non-ischemic ventricular tachycardia: clinical course and long term follow-up in patients without clinically overt heart disease. Circulation. 1989;79:990. CrossrefMedlineGoogle Scholar13. StaffordTrohmanBilskerZamanCastellanosMyerburg WRMLAR. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;7:701-4. CrossrefMedlineGoogle Scholar14. VelebitPodridLownCohenGraboys VPBBT. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation. 1982;65:886-94. CrossrefMedlineGoogle Scholar15. JackmanFridayAndersonAliotClarkLazzara WKJEMR. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31:115-72. CrossrefMedlineGoogle Scholar16. RosenWit MA. Arrhythmogenic actions of antiarrhythmic drugs. Am J Cardiol. 1987;59:10E-8E. CrossrefMedlineGoogle Scholar17. HorowitzGreenspanRaeKaySpielman LAAHS. Proarrhythmic responses during electrophysiologic testing. Am J Cardiol. 1987;59:45E-8E. CrossrefMedlineGoogle Scholar18. BhandariAuRahimtoola APS. Procainamide induced sustained monomorphic ventricular tachycardia in a patient with benign premature ventricular complexes. Can J Cardiol. 1986;2:6-9. MedlineGoogle Scholar19. RuskinMcGovernGaranDiMarcoKelly JBHJE. Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest. N Engl J Med. 1983;309:1302-6. CrossrefMedlineGoogle Scholar20. BuxtonRosenthalMarchlinskiMillerJosephson AMFJM. Ventricular arrhythmias in patients on antiarrhythmic drugs-proarrhythmia or drug failure. J Am Coll Cardiol. 1988;11:182A. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Mark E. Josephson, MDAffiliations: Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAdverse reactions to antiarrhythmic drugsClass I Antiarrhythmic Drugs: Na+ Channel BlockersElectrocautery maze in chronic atrial fibrillation: An early experienceThe long-term outcome of patients with coronary disease and atrial fibrillation undergoing the cox maze procedureThe efficacy of the Cox/maze procedure combined with mitral valve surgery: a matched control studyAtrial FibrillationPrinciples of Pharmacotherapy and Antiarrhythmic DrugsOutcome of valve repair and the cox maze procedure for mitral regurgitation and associated atrial fibrillationProarrhythmiaRecognition and Management of Cardiac Arrhythmias: Part I. General Principles and Supraventricular TachyarrhythmiasRecognition and Management of Cardiac Arrhythmias: Part I. General Principles and Supraventricular TachyarrhythmiasAccessory pathway and atrioventricular node reentrant tachycardia in elderly patients: Clinical features, electrophysiologic characteristics and results of radiofrequency ablationClinical features and electrophysiologic characteristics of accessory atrioventricular pathways and atrioventricular nodal reentrant tachycardia: Comparative study between young and elderly patientsInitial experience with the maze procedure for atrial fibrillationWork-Up and Management of Patients with Sustained and Nonsustained Monomorphic Ventricular TachycardiasInstantaneous cardiac death in the posthospital period after acute myocardial infarctionLow-Dose Amiodarone for Atrial Fibrillation: Time for a Prospective Study?Holly R. Middlekauff, MD, Isaac Wiener, MD, Leslie A. Saxon, MD, William G. Stevenson, MDChronic use of acebutolol in the treatment of cardiac arrhythmiasCardiac Arrhythmias: Premature Beats and Paroxysmal TachycardiasInefficacy and Proarrhythmic Effects of Flecainide and Encainide for Sustained Ventricular Tachycardia and Ventricular FibrillationJohn M. Herre, MD, Christina Titus, RN, Michael Oeff, MD, Michael Eldar, MD, Michael R. Franz, MD, Jerry C. Griffin, MD, Melvin M. Scheinman, MDLate proarrhythmia and understanding the time of occurrence of proarrhythmiaReversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. 15 July 1989Volume 111, Issue 2Page: 101-103KeywordsArrhythmiaAtrial fibrillationBloodDrugsHeartLungsRespiratory system proceduresVentricular tachycardia ePublished: 1 December 2008 Issue Published: 15 July 1989 PDF downloadLoading ...